Eric Karas sold $140k of SPRY
Chief Commercial Officer at ARS Pharmaceuticals, Inc.. 10,000 shares at an average of $14.04, traded Dec 2, 2024, filed Dec 4, 2024.
Score components
- +15RoleOfficer
- +11Trade size$140k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-028349, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 2, 2024 | MOption exercise Common Stock10b5-1 | +3,717 | $1.50 | $5,576 | 9,410 | Dec 4, 2024 |
| Dec 2, 2024 | SOpen-market sale Common Stock10b5-1 | -3,717 | $14.11 | $52k | 5,693 | Dec 4, 2024 |
| Dec 4, 2024 | MOption exercise Common Stock10b5-1 | +6,283 | $1.50 | $9,425 | 11,976 | Dec 4, 2024 |
| Dec 4, 2024 | SOpen-market sale Common Stock10b5-1 | -6,283 | $14.00 | $88k | 5,693 | Dec 4, 2024 |
| Dec 2, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,717 | $0.00 | $0 | 590,871 | Dec 4, 2024 |
| Dec 4, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,283 | $0.00 | $0 | 584,588 | Dec 4, 2024 |
Related signals
Other insiders at ARS Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 34Weak | ARS Pharmaceuticals, Inc. | Kathleen D. Scott Chief Financial Officer | $188k 12,500 shares | -55% | |
| 41Moderate | ARS Pharmaceuticals, Inc. | Richard E Lowenthal PRESIDENT AND CEO | $724k 50,000 shares | -4% | |
| 31Weak | ARS Pharmaceuticals, Inc. | Sarina Tanimoto CHIEF MEDICAL OFFICER | $704k 50,000 shares | -4% | |
| 21Weak | ARS Pharmaceuticals, Inc. | Eric Karas Chief Commercial Officer | $255k 15,000 shares | -59% | |
| 50Moderate | ARS Pharmaceuticals, Inc. | James E Flynn owner | $14M 740,149 shares | -14% | |
| 21Weak | ARS Pharmaceuticals, Inc. | Eric Karas Chief Commercial Officer | $240k 15,000 shares | -66% | |
| 63Notable | ARS Pharmaceuticals, Inc. | Kathleen D. Scott Chief Financial Officer | $705k 50,000 shares | -87% | |
| 60Notable | ARS Pharmaceuticals, Inc. | Brent L Saunders director | $1.7M 120,000 shares | -100% | |
| 60Notable | ARS Pharmaceuticals, Inc. | Alexander A Fitzpatrick Chief Legal Officer | $1.5M 102,969 shares | -53% | |
| 5Weak | ARS Pharmaceuticals, Inc. | Laura Shawver director | $615k 50,002 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.